USA flag logo/image

An Official Website of the United States Government

Defining Therapeutic Potential of Clonal Stem Cell Populations using Targeted…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89173
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
GM083397
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ADVANCED CELL TECHNOLOGY
ADVANCED CELL TECHNOLOGY 381 PLANTATION ST WORCESTER, MA 01605
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Defining Therapeutic Potential of Clonal Stem Cell Populations using Targeted Nan
Agency: HHS
Contract: 1R43GM083397-01
Award Amount: $199,532.00
 

Abstract:

Project Summary Embryonic stem cells offer considerable potential for cell replacement therapy where cells have been lost to injury or disease because of their capacity for continual self renewal and ability to differentiate into virtually any cell type or tissue. Currently, however the process by which human embryonic stem cells (hESCs) differentiate into various mature functional cell types is poorly understood and there is a critical unmet need for methods of expanding and differentiating hESCs into desi rable cell types such as epithelial, dermal, endothelial, cardiac and skeletal myocytes, etc. Scientists at Advanced Cell Technology have isolated hundreds of clonal cell populations (called lineage restricted cells, LRCs) derived from differentiating hESC s which appear to be both expandable in culture and have the properties of early progenitor cells of a multitude of mature cell types. We would like to study LRC differentiation in the context of a differentiating culture of hESCs where they receive signal s from surrounding cells and matrix to better understand their therapeutic potential and how to direct their differentiation in culture. Near term, our goal is to identify specific targeting peptides for LRCs using phage display. Selection on these homogen eous progenitor populations will allow us to identify specific targeting peptides that target surface markers that might otherwise be under-represented when selecting on a hererogeneous population of differentiating hESCs. We will track the developmental f ate of targeted LRCs in their native context of differentiating hESCs using quantum dot conjugated targeting peptides. These tools will allow use to study the differentiation of specific progenitor cells as it occurs in real time using time-lapse imaging. Multiplex labeling with 2 or more peptides will allow us to trace progenitor cell interactions during in vitro differentiation on hESCs. These studies will be used to select LRCs with high therapeutic potential and to develop methods for LRC differentiatio n. Our long term goal is to develop selected LRCs for use in regenerative therapies for skin, vasculature, and heart as well as commercialization of the LRCs and their peptide targeting agents as research reagents. . Project Narrative Embryonic stem cells offer considerable potential for cell replacement therapy where cells have been lost to injury or disease because of their capacity for continual self renewal and ability to differentiate into virtually any cell type or tissue. There is a critical unmet ne ed for methods of expanding and differentiating hESCs in-vitro into desirable cell types such as skin, heart muscle, blood vessels, etc. We have isolated hundreds of pure lineage restricted cells (LRCs) derived from hESCs which are expandable in culture an d have the properties of early progenitor cells of a multitude of mature cell types. Near term, our goal is to label specific LRCs with quantum dot labeled targeting agents so that we can track the developmental fate of LRCs in cultures of differentiating hESCs and thus determine their therapeutic potential. Our long term goal is to develop selected LRCs for use in regenerative therapies for skin, vasculature, and heart among others as well as commercialization of the LRCs and their peptide targeting agents as research reagents.

Principal Investigator:

Business Contact:

Small Business Information at Submission:

ADVANCED CELL TECHNOLOGY
ADVANCED CELL TECHNOLOGY 381 PLANTATION ST WORCESTER, MA 01605

EIN/Tax ID: 010489138
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No